NCT00117637View on ClinicalTrials.gov

BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

189

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

September 30, 2006

Study Completion Date

March 31, 2009

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

Sorafenib (Nexavar, BAY43-9006)

Multi kinase inhibitor

DRUG

Interferon

Interferon

Trial Locations (42)

115

Kiev

12203

Berlin

13273

Marseille

20246

Hamburg

21701

Frederick

31052

Toulouse

33000

Bordeaux

40225

Düsseldorf

44805

Nantes

55131

Mainz

59020

Lille

60488

Frankfurt am Main

60637

Chicago

61024

Kharkiv

69008

Lyon

75246

Dallas

75908

Paris

79031

Lviv

80010

Aurora

81377

München

83092

Donetsk

89075

Ulm

89135

Las Vegas

94805

Villejuif

95817

Sacramento

97239

Portland

98101

Seattle

115478

Moscow

125284

Moscow

197758

Saint Petersburg

420029

Kazan'

610021

Kirov

44195-0002

Cleveland

80-210

Gdansk

31-115

Krakow

61-878

Poznan

70-111

Szczecin

02-781

Warsaw

04-141

Warsaw

50-043

Wroclaw

SW3 6JJ

London

SM2 5PT

Sutton

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00117637 - BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter